Vaccine for Diabetes-Where Do We Stand?

Int J Mol Sci. 2022 Aug 22;23(16):9470. doi: 10.3390/ijms23169470.

Abstract

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.

Keywords: GLP; clinical trials; diabetes; insulin; vaccines.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Animals
  • Autoimmunity
  • Diabetes Mellitus, Type 2* / prevention & control
  • Humans
  • Middle Aged
  • Prospective Studies
  • T-Lymphocytes
  • Vaccines* / therapeutic use

Substances

  • Vaccines